Previous Close | 6.40 |
Open | 6.40 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 134.00 |
Expire Date | 2024-06-28 |
Day's Range | 6.40 - 6.40 |
Contract Range | N/A |
Volume | |
Open Interest | 3 |
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these ...
The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) ...